Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Promising approaches in acute leukemia.

J Cortes1, H M Kantarjian

  • 1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Investigational New Drugs
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving toward individualized target-based therapies in acute myeloid leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

The pharmacogenomics journal·2017
Same author

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.

Blood cancer journal·2017
Same author

Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Leukemia·2017
Same author

Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.

Leukemia·2017

Advances in understanding acute leukemia molecular mechanisms are yielding novel therapies. New treatments, including targeted therapies and novel chemotherapeutics, offer hope for curing more leukemia patients.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Significant progress has been made in acute leukemia treatment, yet many patients still succumb to the disease.
  • Recent breakthroughs in understanding molecular mechanisms have identified new therapeutic targets.
  • Existing treatments face challenges, including drug resistance and disease progression.

Purpose of the Study:

  • To review promising novel therapeutic approaches for acute leukemias.
  • To highlight advancements in targeted therapies and novel chemotherapeutic agents.
  • To discuss the potential of new treatments to improve patient outcomes.

Main Methods:

  • Review of current research on novel anti-leukemia agents.
  • Analysis of targeted therapies inhibiting molecules like tyrosine kinases and Ras.

Related Experiment Videos

  • Examination of chemotherapeutic agents with new mechanisms of action (e.g., topoisomerase I inhibitors, demethylating agents).

    • Main Results:

    • Novel therapeutic strategies are emerging, targeting specific molecular pathways in acute leukemias.
    • Approaches include novel chemotherapeutics, reversal of drug resistance, monoclonal antibodies, and targeted kinase inhibitors.
    • Many of these promising agents are in early-stage research.

    Conclusions:

    • New therapeutic strategies hold significant promise for improving acute leukemia treatment.
    • Targeted therapies and novel agents offer hope for a future cure for most leukemia patients.
    • Continued research into these novel approaches is crucial for advancing leukemia care.